2nd May 2024
Professor Powles has been recognised for his transformative clinical work delivering a life-extending treatment for severe bladder cancer.
Read more15th December 2023
Professor Powles has been recognised for his transformative clinical work delivering a life-extending treatment for severe bladder cancer.
Read more10th February 2022
An immunotherapy drug called ‘pembrolizumab’ has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by Professor Peter Schmid from Queen Mary University of London and Barts Health NHS Trust.
Read more29th November 2021
During the interview, Professor Lemoine highlighted that studies being undertaken across the country aim to elucidate the mechanisms involved in long COVID, and further studies are being set up to identify treatments that will be effective against the disease.
Read more11th November 2021
Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.
Read more15th September 2020
Professor John Gribben, Lead for the Centre for Haemato-Oncology at Barts Cancer Institute and Consultant Haematologist at Barts Health NHS Trust, is part of a new BBC Two series called The Diagnosis Detectives. Professor Gribben is one of a panel of 12 of the UK’s leading medical experts who have been assembled to diagnose patients with life-changing symptoms that have puzzled other doctors and remained undiagnosed.
Read more